Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 1835 results for carers

  1. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development Reference number: GID-TA11040 Expected publication date: TBC

  2. Self‑harm (QS34)

    This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.

  3. Joint replacement (primary): hip, knee and shoulder (QS206)

    This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.

  4. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

  5. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

  6. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

  7. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

  8. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    Awaiting development Reference number: GID-TA11769 Expected publication date: TBC

  9. Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

  10. Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost effective in reducing early and emerging behaviour that challenges in the short- and medium-term compared with treatment as usual?

    Question Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost...

  11. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

  12. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

  13. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

  14. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    In development Reference number: GID-TA11425 Expected publication date: TBC

  15. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development Reference number: GID-TA11494 Expected publication date: TBC